

Final Conclusions

LYMErix

Lyme Disease Vaccine (Recombinant OspA)

Final Conclusions

- **Experience in > 18,000 subjects in controlled investigations**
- **1.4 million doses distributed in the marketplace**
- **All the additional data confirm the safety profile defined at time of licensure**
- **As for all vaccines, GSK is committed to continuing the safety assessment of LYMErix in close collaboration with CBER**

LYMErix
Lyme Disease Vaccine (Recombinant OspA)

FDA Advisory Committee Meeting
Vaccines and Related Biological
Products

January 31, 2001